Stellar Biotechnologies Inc (SBOT) : Frigate Ventures Lp added new position in Stellar Biotechnologies Inc during the most recent quarter end. The investment management firm now holds 843,750 shares of Stellar Biotechnologies Inc which is valued at $2,337,188 , the company said in a statement filed on Aug 12, 2016 with the SEC.Stellar Biotechnologies Inc makes up approximately 0.85% of Frigate Ventures Lp’s portfolio.
Other Hedge Funds, Including , Tower Research Capital (trc) reduced its stake in SBOT by selling 644 shares or 46.43% in the most recent quarter. The Hedge Fund company now holds 743 shares of SBOT which is valued at $2,058.
Many Wall Street Analysts have commented on Stellar Biotechnologies Inc. Shares were Reiterated by Maxim Group on Aug 1, 2016 to “Buy” and Lowered the Price Target to $ 7 from a previous price target of $17 .
Stellar Biotechnologies Inc. (Stellar) is a biotechnology company. The Company is engaged in the aquaculture research and development manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH is a high molecular weight and immune-stimulating protein. It operates under the brand name Stellar KLH. Its products include Stellar KLH protein in various grades formulations and configurations for both clinical and preclinical applications. Stellar KLH can be used for therapeutic vaccine conjugation as a carrier molecule in immunotherapies and as an immune stimulant in immunotoxicology applications. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies targeting cancer immune disorders Alzheimer’s disease and inflammatory diseases or it can be used as a finished injectable product in the immunodiagnostic market for measuring immune response in patients and research settings.